To include your compound in the COVID-19 Resource Center, submit it here.

EMA to review Teva's migraine candidate

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv: TEVA) said EMA accepted for review an MAA for

Read the full 165 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE